PHILADELPHIA (September 16, 2021) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company’s Chief Legal Officer effective September 16, 2021.
“John’s breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team,” said John Furey, Chief Executive Officer. “As we work to expand our platform to address a variety of solid tumors, John’s expertise will be an essential part of the development of these assets.”
Mr. Limongelli is an accomplished executive officer and lawyer with nearly 25 years of public company experience. Prior to Imvax, Mr. Limongelli served as Senior Vice President, General Counsel and Corporate Secretary at Neos Therapeutics, Inc., a publicly traded biotechnology company. He previously worked at Trevena, Inc. (NASDAQ: TRVN), where he was Senior Vice President, General Counsel and Chief Administrative Officer. Earlier in his career Mr. Limongelli held high-level legal roles at Cigna Corporation, Adolor Corporation, and Cephalon, Inc. He began his legal career in private practice with Morgan, Lewis & Bockius, LLP, and was a Certified Public Accountant with KPMG LLP. Mr. Limongelli obtained both his J.D. and MBA from Temple University.
“I’m excited to join the Imvax team in this time of rapid growth of the Company’s therapeutic portfolio,” said Mr. Limongelli. “Imvax’s unique immuno-oncology platform has shown enormous potential, and I am looking forward to working closely with the team to leverage this approach to deliver novel therapeutics for patients.”
About Imvax, Inc.
Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.